Tenepride Tablets (Teneligliptin)

• Composition :
  Each film-coated tablet contains Teneligliptin 20 mg.
• Indications :
  Indicated for the treatment of Type 2 Diabetes Mellitus as a monotherapy, adjunct to diet and exercise.
• Pharmacodynamics :
  Teneligliptin is a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones. Concentrations of the active intact hormones are increased by teneligliptin, thereby increasing and prolonging the action of these hormones. Incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal. These hormones are rapidly inactivated by the enzyme, DPP-4.
• Dosage and administration :
  The usual adult dosage is 20 mg of teneligliptin administered orally once daily. If efficacy is insufficient, the dose may be increased up to 40 mg once daily while closely monitoring the clinical course.
• Contraindications :
  Contraindicated in patients with known hypersensitivity to the drug. Severe ketosis, diabetic coma or history of diabetic coma, type 1 diabetic patients.
• Precautions and warnings :
  Patients with advanced liver failure, congestive heart failure (NYHA category III-IV), pituitary insufficiency or adrenal insufficiency, poor nutritional state, starvation, an irregular dietary intake, or debilitating condition, intense muscle movement or excessive alcohol intake, low serum potassium, congenital prolonged QT syndrome, history of Torsades de pointes or patients using antiarrhythmic drugs (may cause QT prolongation).
• Use in pregnancy, lactation & pediatrics :
  The safety of this product in pregnant women has not been established. Breast-feeding must be discontinued during administration of this product in lactating women. Safety and effectiveness in children younger than 18 years of age have not been established.
• Drug interactions :
  Teneligliptin should be used with caution along with drugs that can enhance the blood glucose lowering effect (like β blockers, MAO inhibitors, etc.) and drugs that can reduce the blood glucose lowering effect (like steroids, thyroid hormones, etc.).
• Adverse reactions :
  The most common adverse reactions reported are abnormal stools, hypoglycemia, myalgia, lightheaded, dyspnea, nail disorder, rash, sweating increased, taste disorder, chest discomfort, chills, flu syndrome, flushing and palpitation, intestinal obstruction elevated liver enzymes.
• Therapy Area :
  Anti-Diabetic agents